The Effects of Cannabidiol and ∆-9-THC in Humans
This trial is active, not recruiting.
|Treatments||cannabidiol, delta-9-thc, placebo|
|Start date||June 2010|
|End date||July 2017|
|Trial size||75 participants|
|Trial identifier||NCT01180374, 1001006240|
Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD. This study will characterize the interactive effects of the two major components of cannabis i.e. Δ-9-THC and CBD.
|Intervention model||crossover assignment|
|Primary purpose||basic science|
|Masking||participant, care provider, investigator, outcomes assessor|
time frame: Baseline, +15, +80, +240
All participants from 18 years up to 55 years old.
Inclusion Criteria: - Exposed to Cannabis at least once in lifetime Exclusion Criteria: - Cannabis Naive
|Official title||Cannabidiol Modulation of ∆-9-THC's Psychotomimetic Effects in Healthy Humans|
|Principal investigator||Mohini Ranganathan, M.D|
Call for more information